Evidence map›Paper›PMID 36548228›Full record

ArticlePloS one2022

Quality control on digital cancer registration.

Stefano Guzzinati, Jessica Battagello, Emanuela Bovo, Maddalena Baracco, Susanna Baracco, Eva Carpin, Antonella Dal Cin, Anna Rita Fiore, Alessandra Greco, Giancarla Martin and 7 more

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Stefano GuzzinatiRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.ORCID 0000-0002-4908-5506
Jessica BattagelloRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Emanuela BovoRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Maddalena BaraccoRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Susanna BaraccoRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Eva CarpinRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Antonella Dal CinRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Anna Rita FioreRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Alessandra GrecoRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Giancarla MartinRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Laura MemoRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Daniele MonettiRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.ORCID 0000-0002-9656-6695
Silvia RizzatoRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Carmen StoccoRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Sara ZamberlanRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Manuel ZorziRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.
Massimo RuggeRegional Epidemiology Service, Veneto Cancer Registry (RTV), Azienda Zero, Padova, Italia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Population-based cancer registration methods are subject to internationally-established rules. To ensure efficient and effective case recording, population-based cancer registries widely adopt digital processing (DP) methods. At the Veneto Tumor Registry (RTV), about 50% of all digitally-identified (putative) cases of cancer are further profiled by means of registrars' assessments (RAs). Taking these RAs for reference, the present study examines how well the registry's DP performs. A series of 1,801 (putative) incident and prevalent cancers identified using DP methods were randomly assigned to two experienced registrars (blinded to the DP output), who independently re-assessed every case. This study focuses on the concordance between the DP output and the RAs as concerns cancer status (incident versus prevalent), topography, and morphology. The RAs confirmed the cancer status emerging from DP for 1,266/1,317 incident cancers (positive predictive value [PPV] = 96.1%) and 460/472 prevalent cancers (PPV = 97.5%). This level of concordance ranks as "optimal", with a Cohen's K value of 0.91. The overall prevalence of false-positive cancer cases identified by DP was 2.9%, and was affected by the number of digital variables available. DP and the RAs were consistent in identifying cancer topography in 88.7% of cases; differences concerned different sites within the same anatomo-functional district (according to the International Agency for Research on Cancer [IARC]) in 9.6% of cases. In short, using DP for cancer case registration suffers from only trivial inconsistencies. The efficiency and reliability of digital cancer registration is influenced by the availability of good-quality clinical information, and the regular interdisciplinary monitoring of a registry's DP performance.

Indexed as

NeoplasmsHumansPrevalenceQuality ControlRegistriesReproducibility of Results

Identifiers

PMID36548228
PMCPMC9778557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.